Actualités et Activités de Canbridge Pharmaceuticals
Présence
Canbridge Pharmaceuticals est une société cotée sous le symbole boursier 1228 (CN).
Dirigeants
Voir l'organigramme avec ses 27 principaux dirigeants
Biographies les plus recherchées chez Canbridge Pharmaceuticals
- James Xue, Chairman of the Board and Chief Executive Officer
- Lan Hu, Independent Director
- Peng Kuan Chan, Independent Non-Executive Director
Créer une alerte
pour suivre les mouvements de dirigeants chez Canbridge Pharmaceuticals.
Pharmacie
Canbridge Pharmaceuticals a 1 833 concurrents dont Pfizer (Etats—Unis), Sanofi (France) et Eli Lilly (Etats—Unis).
Actualités en fusion/acquisition en Pharmacie.
- Imbria Pharmaceuticals vient d'annoncer une levée de fonds de 58 millions de dollars. (publié le 10 avril 2025).
- Clario a acquis NRx Pharmaceuticals (publié le 18 mars 2025).
- Knight Therapeutics has announced the acquisition of Paladin Labs (publié le 12 mars 2025).
Contacts en Pharmacie
Actualités
Derniers communiqués de presse par Canbridge Pharmaceuticals
- CANbridge Announces that Velaglucerase-beta for Injection Successfully Passed the Pre-approval inspection and Pre - marketing GMP Compliance Inpection for the Pilot Biological Product of Divided manufacturing
- CANbridge Announces Marketing Approval of Livmarli® in Taiwan for the Treatment of Cholestatic Pruritus in PFIC Patients
- CANbridge Announces Expansion of Livmarli® Label to Include ALGS Patients as Young as 2 Months in Taiwan
- CANbridge and Scriptr Global Announce Publication in the Journal Science Reporting the Discovery of the StitchR™ RNA Assembly Technology and its Application for the Treatment of Muscular Dystrophies
- CANbridge Pharmaceuticals CAN103 New Drug Application (NDA), for Gaucher disease, Accepted by China’s National Medical Products Administration
- CANbridge Pharmaceuticals Successfully Obtains Drug Manufacturing License Type B Certificate
- CANbridge Pharmaceuticals’ CAN103 for Gaucher Disease Granted Priority Review Status by CDE of the NMPA
- CANbridge Reports Positive Topline Data from CAN103 Pivotal Trial for Gaucher Disease in China, Plans NDA Filing in Q4 2024
- CANbridge’s Livmarli Is Recommended in The “ Expert Consensus on Diagnosis and Treatment of ALGS Associated Liver Disease” Published By The Chinese Journal of Pediatrics
- CANbridge Announces Last Patient Last Visit in CAN103 Phase 2/Registration Trial for Gaucher Disease
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Canbridge Pharmaceuticals
- Canbridge Pharmaceuticals sur Wikipédia, Google News & Yahoo Finance en 1-click
- Canbridge Pharmaceuticals sur LinkedIn, Twitter & YouTube en 1-click
